Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10383 MAD study in healthy adults
NCT06092983Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic cough comparing HS-10383 with Placebo (2 arms). Primary endpoint: Number and severity of treatment emergent adverse events up to 15 days. Status: unknown.
02
Drugs
HS-10383
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT06092983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092983.